GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioLine Rx Ltd (STU:YP2) » Definitions » E10

BioLine Rx (STU:YP2) E10 : €-108.33 (As of Sep. 2024)


View and export this data going back to 2014. Start your Free Trial

What is BioLine Rx E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

BioLine Rx's adjusted earnings per share data for the three months ended in Sep. 2024 was €-2.624. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is €-108.33 for the trailing ten years ended in Sep. 2024.

During the past 3 years, the average E10 Growth Rate was 23.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of BioLine Rx was 23.40% per year. The lowest was 23.40% per year. And the median was 23.40% per year.

As of today (2025-03-23), BioLine Rx's current stock price is €4.04. BioLine Rx's E10 for the quarter that ended in Sep. 2024 was €-108.33. BioLine Rx's Shiller PE Ratio of today is .


BioLine Rx E10 Historical Data

The historical data trend for BioLine Rx's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioLine Rx E10 Chart

BioLine Rx Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only -246.40 -283.15 - - -126.74

BioLine Rx Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -136.59 -126.74 -123.22 -110.84 -108.33

Competitive Comparison of BioLine Rx's E10

For the Biotechnology subindustry, BioLine Rx's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioLine Rx's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioLine Rx's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where BioLine Rx's Shiller PE Ratio falls into.



BioLine Rx E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, BioLine Rx's adjusted earnings per share data for the three months ended in Sep. 2024 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Sep. 2024 (Change)*Current CPI (Sep. 2024)
=-2.624/133.0289*133.0289
=-2.624

Current CPI (Sep. 2024) = 133.0289.

BioLine Rx Quarterly Data

per share eps CPI Adj_EPS
201412 -58.392 99.070 -78.408
201503 -55.994 99.621 -74.772
201506 -48.114 100.684 -63.571
201509 -16.038 100.392 -21.252
201512 -38.556 99.792 -51.397
201603 -32.328 100.470 -42.804
201606 -37.380 101.688 -48.901
201609 -42.768 101.861 -55.854
201612 -39.816 101.863 -51.998
201703 -44.880 102.862 -58.042
201706 -26.700 103.349 -34.368
201709 -35.238 104.136 -45.015
201712 -35.490 104.011 -45.391
201803 -29.196 105.290 -36.888
201806 -25.680 106.317 -32.132
201809 -30.852 106.507 -38.535
201812 -26.370 105.998 -33.095
201903 -26.550 107.251 -32.931
201906 -21.240 108.070 -26.146
201909 -16.344 108.329 -20.070
201912 -32.400 108.420 -39.754
202003 -21.720 108.902 -26.532
202006 -15.984 108.767 -19.549
202009 -10.188 109.815 -12.342
202012 -19.728 109.897 -23.881
202103 -10.080 111.754 -11.999
202106 -4.980 114.631 -5.779
202109 -5.100 115.734 -5.862
202112 0.000 117.630 0.000
202203 -5.448 121.301 -5.975
202206 -5.676 125.017 -6.040
202209 -6.060 125.227 -6.438
202212 0.000 125.222 0.000
202303 -5.604 127.348 -5.854
202306 -11.076 128.729 -11.446
202309 -11.244 129.860 -11.518
202312 -5.502 129.419 -5.655
202403 -0.354 131.776 -0.357
202406 0.225 132.554 0.226
202409 -2.624 133.029 -2.624

Add all the adjusted EPS together and divide 10 will get our e10.


BioLine Rx  (STU:YP2) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


BioLine Rx E10 Related Terms

Thank you for viewing the detailed overview of BioLine Rx's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


BioLine Rx Business Description

Traded in Other Exchanges
Address
2 HaMa’ayan Street, Modi’in, ISR, 7177871
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.

BioLine Rx Headlines

No Headlines